Table 2.

Results of pathway enrichment analysis.

Pathway Name	Significantly Enriched Pathways a
	HCC vs. Control	HCC vs. LC	LC vs. Control
Alanine, aspartate, and glutamate metabolism	o	o	o
Aminoacyl-tRNA biosynthesis	o	o	o
Arginine and proline metabolism	o	o	o
Arginine biosynthesis	o	o	o
D-glutamine and D-glutamate metabolism	o	o	x
Glyoxylate and dicarboxylate metabolism	o	o	o
Nitrogen metabolism	o	o	x
Phenylalanine metabolism	o	o	o
Phenylalanine, tyrosine, and tryptophan biosynthesis	o	o	o
Primary bile acid biosynthesis	o	o	o
Valine, leucine, and isoleucine biosynthesis	o	o	x
Glutathione metabolism	x	o	o
Ascorbate and aldarate metabolism	o	x	x
Butanoate metabolism	o	x	o
Citrate cycle (TCA cycle)	o	x	o
Glycine, serine, and threonine metabolism	o	x	x
Histidine metabolism	o	x	o
Porphyrin and chlorophyll metabolism	o	x	o
Pyruvate metabolism	o	x	x
Taurine and hypotaurine metabolism	o	x	x

^a FDR < 0.2; HCC: hepatocellular carcinoma, LC: liver cirrhosis, o: significant enrichment, x: nonsignificant enrichment, TCA: taurocholic acid.